GlassScriptPhysician profile
Todd T Davis
NPI 1629063169
$8,986.45
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,355 · 2020: $1,281 · 2021: $1,260 · 2022: $1,441 · 2023: $2,209 · 2024: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,551 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,550.52 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,531.95 | 2019-2024 | Skyrizi, Rinvoq, Alloderm |
| Sun Pharmaceutical Industries INC. | $855.29 | 2019-2023 | Ilumya, Winlevi |
| Janssen Biotech, INC. | $839.50 | 2019-2024 | Tremfya, Simponi Aria, Stelara |
| Regeneron Healthcare Solutions, INC. | $770.32 | 2020-2024 | Libtayo, Dupixent |
| Lilly USA, LLC | $582.08 | 2019-2024 | Taltz, Olumiant |
| Genzyme Corporation | $570.53 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $470.25 | 2019-2024 | |
| Galderma Laboratories, L.P. | $449.46 | 2019-2024 | |
| Amgen INC. | $387.31 | 2020-2024 | Otezla |
| Pfizer INC. | $385.46 | 2019-2024 | |
| Vyne Pharmaceuticals INC. | $264.12 | 2020-2021 | |
| Ucb, INC. | $246.52 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $212.81 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $190.70 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $170.91 | 2022-2024 | Sotyktu |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $132.90 | 2020-2023 | Adbry |
| Incyte Corporation | $129.01 | 2022-2024 | Opzelura |
| Almirall LLC | $113.15 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $102.02 | 2019-2024 | Arazlo, Jublia, Cabtreo |
| Biofrontera INC. | $82.72 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Celgene Corporation | $62.27 | 2019 | |
| Sandoz INC. | $59.88 | 2023-2024 | Hyrimoz |
| Mayne Pharma Commercial LLC | $52.69 | 2019 | |
| Verrica Pharmaceuticals INC. | $51.09 | 2023-2024 | Ycanth |
| Strata Skin Sciences, INC. | $47.36 | 2021 | |
| Merck Sharp & Dohme LLC | $40.73 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $37.99 | 2021-2022 | |
| Medtronic Vascular, INC. | $36.85 | 2019 | |
| Organogenesis INC. | $26.59 | 2020-2021 | |
| Genentech USA, INC. | $23.78 | 2019 | |
| Myriad Genetic Laboratories, INC. | $19.52 | 2021 | |
| Dermira, INC. | $17.67 | 2020 | |
| Merz North America, INC. | $17.15 | 2023 | Xeomin |
| Sensus Healthcare, INC. | $5.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.